{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:17:27Z","timestamp":1765354647959,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"crossref","award":["2013\/13907\u20134","2017\/15175\u20131","2018\/09765\u20133"],"award-info":[{"award-number":["2013\/13907\u20134","2017\/15175\u20131","2018\/09765\u20133"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejphar.2019.172447","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T02:55:29Z","timestamp":1560912929000},"page":"172447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response"],"prefix":"10.1016","volume":"858","author":[{"given":"Mariana G.","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Alejandro","family":"Rojas-Moscoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela M.","family":"Bertollotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuany Z.","family":"Candido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Ricardo de A.","family":"Kiguti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 S.","family":"Pupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"De Nucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fab\u00edola Z.","family":"M\u00f3nica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2019.172447_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23 -adrenoceptor activation and \u03b11-adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/pr.111.004515","article-title":"Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction","volume":"63","author":"Andersson","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172447_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/nau.20999","article-title":"Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action","volume":"30","author":"Andersson","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2019.172447_bib4","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/j.jacc.2011.09.033","article-title":"Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation","volume":"58","author":"Arag\u00f3n","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172447_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.118.250076","article-title":"Inhibition of multidrug resistance proteins by MK 571 enhances bladder, prostate, and urethra relaxation through cAMP or cGMP accumulation","volume":"367","author":"Bertollotto","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jsxm.2017.02.005","article-title":"Inhibition of cyclic GMP export by multidrug resistance protein 4: a new strategy to treat erectile dysfunction?","volume":"14","author":"Boydens","year":"2017","journal-title":"J. Sex. Med."},{"issue":"5068","key":"10.1016\/j.ejphar.2019.172447_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.1378650","article-title":"Nitric oxide: a physiologic mediator of penile erection","volume":"257","author":"Burnett","year":"1992","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.ejphar.2019.172447_bib8","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1111\/bph.14433","article-title":"\u03b23-adrenoceptor stimulation of perivascular adipocytes leads to increased fat cell-derived NO and vascular relaxation small arteries","volume":"175","author":"Bussey","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pros.22930","article-title":"The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?","volume":"75","author":"Calmasini","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2019.172447_bib10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/nau.23171","article-title":"Long-term treatment with the beta-3 agonist, mirabegron, ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice","volume":"36","author":"Calmasini","year":"2016","journal-title":"Neurourol. Urodyn."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib11","first-page":"649","article-title":"Potent and selective human beta(3)-adrenergic receptor antagonists","volume":"290","author":"Candelore","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.172447_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol. Urodyn."},{"issue":"9","key":"10.1016\/j.ejphar.2019.172447_bib13","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1073\/pnas.0931347100","article-title":"Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function","volume":"100","author":"Cirino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172447_bib14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/TCRM.S3336","article-title":"Tadalafil in the treatment of erectile dysfunction","volume":"4","author":"Coward","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bju.13105","article-title":"Pharmacological characterization of the relaxation induced by the soluble guanylyl cyclase activator, BAY 60-2770, in rabbit corpus cavernosum","volume":"116","author":"Estancial","year":"2015","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.ejphar.2019.172447_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","article-title":"Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract","volume":"7","author":"Fibbi","year":"2010","journal-title":"J. Sex. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.eururo.2011.06.037","article-title":"Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"60","author":"Gacci","year":"2011","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.ejphar.2019.172447_bib19","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1046\/j.1432-1327.2001.02233.x","article-title":"Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum","volume":"268","author":"Gopal","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejphar.2019.172447_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bju.13515","article-title":"Mirabegron causes relaxation of human and rat corpus cavernosum: could be a potential therapy for erectile dysfunction?","volume":"118","author":"Gur","year":"2016","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172447_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00210-012-0821-4","article-title":"In vitro and in vivo pharmacological profile of the selective \u03b23-adrenoceptor agonist mirabegron in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172447_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00345-005-0019-1","article-title":"Nitric oxide\/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?","volume":"23","author":"Hedlund","year":"2005","journal-title":"World J. Urol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00210-003-0860-y","article-title":"Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells","volume":"369","author":"Hoffmann","year":"2004","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172447_bib24","doi-asserted-by":"crossref","first-page":"C1344","DOI":"10.1152\/ajpcell.00001.2008","article-title":"Stimulation of beta-3-adrenoceptors relaxes rat urinary bladder smooth muscle via activation of the large-conductance Ca2+-activated K+ channels","volume":"295","author":"Hristov","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"41","key":"10.1016\/j.ejphar.2019.172447_bib25","doi-asserted-by":"crossref","first-page":"16624","DOI":"10.1073\/pnas.1213790109","article-title":"Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection","volume":"109","author":"Hurt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.ejphar.2019.172447_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.clinthera.2015.02.021","article-title":"Pharmacokinetics of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder, in healthy east asian subjects","volume":"37","author":"Iitsuka","year":"2015","journal-title":"Clin. Ther."},{"issue":"12","key":"10.1016\/j.ejphar.2019.172447_bib27","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1111\/j.1743-6109.2008.01000.x","article-title":"Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men","volume":"5","author":"Irwin","year":"2008","journal-title":"J. Sex. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2019.172447_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/17425255.2013.786700","article-title":"The pharmacokinetic evaluation of mirabegron as na overactive bladder therapy option","volume":"9","author":"Kashyap","year":"2013","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/nau.22732","article-title":"Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction","volume":"35","author":"Kawai","year":"2016","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"10.1016\/j.ejphar.2019.172447_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ijcp.12176","article-title":"Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis","volume":"67","author":"Kirby","year":"2013","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14728220903540257","article-title":"Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease","volume":"14","author":"Kohler","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.ejphar.2019.172447_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2008.08.062","article-title":"The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors","volume":"55","author":"K\u00f6hler","year":"2009","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172447_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.eururo.2005.02.001","article-title":"Erectile dysfunction and lower urinary tract symptoms secondary to BPH","volume":"47","author":"McVary","year":"2005","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1590\/s0102-865020170201","article-title":"The renoprotective effect of oral Tadalafil pretreatment on ischemia\/reperfusion injury in rats","volume":"32","author":"Medeiros","year":"2017","journal-title":"Acta Cir. Bras."},{"key":"10.1016\/j.ejphar.2019.172447_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bcp.2018.03.028","article-title":"Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy","volume":"152","author":"Mendes-Silverio","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172447_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.phrs.2017.07.025","article-title":"\u03b2(3) adrenergic receptor activation relaxes human corpus cavernosum and penile artery through a hydrogen sulfide\/cGMP-dependent mechanism","volume":"124","author":"Mitidieri","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"16","key":"10.1016\/j.ejphar.2019.172447_bib51","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b2(3) -adrenoceptor agonist mirabegron increases human atrial force through \u03b2(1) -adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2019.172447_bib37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.yjmcc.2010.02.011","article-title":"Beta 3-adrenoceptor regulation of nitric oxide in the cardiovascular system","volume":"48","author":"Moens","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.ejphar.2019.172447_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2019.172447_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference, Impotence","year":"1993","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172447_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ucl.2016.04.004","article-title":"Antimuscarinics, \u03b2-3 agonists, and phosphodiesterase inhibitors in the treatment of male lower urinary tract symptoms: an evolving paradigm","volume":"43","author":"Osman","year":"2016","journal-title":"Urol. Clin."},{"issue":"7","key":"10.1016\/j.ejphar.2019.172447_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrurol.2013.101","article-title":"The role of phosphodiesterases in bladder pathophyisiology","volume":"10","author":"Rahnama\u2019i","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2019.172447_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199201093260203","article-title":"Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission","volume":"326","author":"Rajfer","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2019.172447_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1440-1681.2005.04222.x","article-title":"New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation","volume":"32","author":"Tanaka","year":"2005","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1432-1033.1991.tb15824.x","article-title":"Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells","volume":"196","author":"Tate","year":"1991","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172447_bib46","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.103.062026","article-title":"Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum","volume":"309","author":"Teixeira","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2019.172447_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3940(97)00388-1","article-title":"Subtyping of alpha1-adrenoceptors responsible for the contractile response in the rat corpus cavernosum","volume":"228","author":"Tong","year":"1997","journal-title":"Neurosci Lett 13"},{"key":"10.1016\/j.ejphar.2019.172447_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2005.06.029","article-title":"Involvement of cyclic AMP-dependent and \u2013independent mechanisms in the relaxation of rat detrusor muscle via \u03b2\u2013adrenoceptors","volume":"518","author":"Uchida","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2019.172447_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2013.10.039","article-title":"The new radioligand [(3)H]-L 748,337 differentialy labels human and rat \u03b23-adrenoceptors","volume":"720","author":"Van Wieringen","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.ejphar.2019.172447_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00210-006-0127-5","article-title":"Tools to study beta3-adrenoceptors","volume":"374","author":"Vrydag","year":"2007","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919303991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:19:10Z","timestamp":1564359550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919303991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":50,"alternative-id":["S0014299919303991"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172447","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172447"}}